Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2011 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Income from Continuing Operations came in at 40335000.0 in Q1 2026, down 155.66% year-on-year from 72470708.92 in Q1 2025, and up 13.86% quarter-over-quarter from 46823000.0 in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 40335000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 155.66% year-over-year to 40335000.0 in Q1 2026; TTM through Mar 2026 was 147367000.0, a 9.88% decrease from a year earlier, with the FY2025 full-year figure at 127666000.0, up 36.02% from the prior year.
- Income from Continuing Operations climbed to 40335000.0 in Q1 2026 per TNXP's latest filing, from 46823000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15777000.0 in Q1 2025 and bottomed at 78888000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 29140000.0 (2022), against an average of 31448882.35.
- Across the five-year window, Income from Continuing Operations slumped 170.68% in 2024 and surged 64.08% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 31831000.0 in 2022, then rose by 15.79% to 26805000.0 in 2023, then grew by 15.88% to 22549000.0 in 2024, then slumped by 107.65% to 46823000.0 in 2025, then advanced by 13.86% to 40335000.0 in 2026.
- Per Business Quant, the three latest TNXP Income from Continuing Operations figures stand at 40335000.0 (Q1 2026), 46823000.0 (Q4 2025), and 31871000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Tonix Pharmaceuticals Holding | 141.94 Mn | 141.94 Mn | 5.30 Mn | -40.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.34 Mn |
| Dec 31, 2025 | -46.82 Mn |
| Sep 30, 2025 | -31.87 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Mar 31, 2025 | -15.78 Mn |
| Dec 31, 2024 | -22.55 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -78.89 Mn |
| Mar 31, 2024 | -23.14 Mn |
| Dec 31, 2023 | -26.81 Mn |
| Sep 30, 2023 | -29.23 Mn |
| Jun 30, 2023 | -29.14 Mn |
| Mar 31, 2023 | -33.14 Mn |
| Dec 31, 2022 | -31.83 Mn |
| Sep 30, 2022 | -29.14 Mn |
| Jun 30, 2022 | -24.15 Mn |
| Mar 31, 2022 | -26.57 Mn |
| Dec 31, 2021 | -29.71 Mn |
| Sep 30, 2021 | -18.67 Mn |
| Jun 30, 2021 | -23.58 Mn |